Radius Health Inc (NASDAQ:RDUS) was the recipient of some unusual options trading activity on Friday. Traders bought 3,020 call options on the stock. This represents an increase of approximately 1,279% compared to the typical daily volume of 219 call options.
RDUS has been the subject of several recent research reports. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Radius Health in a research report on Thursday. Citigroup initiated coverage on shares of Radius Health in a research report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average price target of $48.00.
Shares of Radius Health (RDUS) opened at $38.02 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16. The stock has a market cap of $1,695.39, a P/E ratio of -7.00 and a beta of 1.10.
In other Radius Health news, VP Brent Hatzis-Schoch purchased 1,778 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the acquisition, the vice president now owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was acquired at an average price of $26.25 per share, for a total transaction of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The disclosure for this purchase can be found here. Insiders purchased 158,578 shares of company stock worth $4,659,916 in the last 90 days. 15.00% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its position in shares of Radius Health by 0.9% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 182,575 shares of the biopharmaceutical company’s stock worth $5,801,000 after buying an additional 1,674 shares in the last quarter. Belpointe Asset Management LLC acquired a new stake in shares of Radius Health during the third quarter worth approximately $474,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Radius Health during the third quarter worth approximately $110,000. Point72 Asset Management L.P. acquired a new stake in shares of Radius Health during the third quarter worth approximately $17,236,000. Finally, Orbimed Advisors LLC grew its position in shares of Radius Health by 59.5% during the third quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock worth $43,284,000 after buying an additional 418,700 shares in the last quarter.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.